{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-rhabdomyosarcoma+Soft-tissue+Sarcoma",
    "query": {
      "condition": "Non-rhabdomyosarcoma Soft-tissue Sarcoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 98,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-rhabdomyosarcoma+Soft-tissue+Sarcoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T04:38:16.547Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00020527",
      "title": "Caspofungin Acetate in Treating Children With Fever and Neutropenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fever, Sweats, and Hot Flashes",
        "Infection",
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Neuroblastoma",
        "Neutropenia",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "caspofungin acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": null,
      "start_date": "2001-03",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 5,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020527"
    },
    {
      "nct_id": "NCT00030108",
      "title": "Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Kidney Cancer",
        "Leukemia",
        "Liver Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 30,
      "start_date": "2001-11",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030108"
    },
    {
      "nct_id": "NCT00769613",
      "title": "Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "cytomegalovirus IE-1-specific cytotoxic T lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytomegalovirus pp65-specific cytotoxic T lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunological diagnostic method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2008-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00769613"
    },
    {
      "nct_id": "NCT03526250",
      "title": "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Recurrent Childhood Ependymoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Kidney Wilms Tumor",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Glioma",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma",
        "Refractory Glioma",
        "Refractory Hepatoblastoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Glioma",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 23,
      "start_date": "2018-08-13",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 115,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03526250"
    },
    {
      "nct_id": "NCT00118326",
      "title": "Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Neuroblastoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": null,
      "start_date": "2003-08",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2010-05-14",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Seattle, Washington",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00118326"
    },
    {
      "nct_id": "NCT00365768",
      "title": "Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Neurotoxicity",
        "Peripheral Neuropathy",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Glutamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "5 Years to 21 Years"
      },
      "enrollment_count": 56,
      "start_date": "2004-10",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2016-09-09",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00365768"
    },
    {
      "nct_id": "NCT07224568",
      "title": "Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor (Excluding CNS)",
        "Hepatocellular Carcinoma",
        "Liver Cell Carcinoma",
        "Liposarcoma",
        "Yolk Sac Tumor",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "SC-CAR.GPC3xIL15.21 CAR T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2026-04-01",
      "completion_date": "2045-08",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224568"
    },
    {
      "nct_id": "NCT04284774",
      "title": "Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Solid Neoplasm",
        "Recurrent Adrenal Gland Pheochromocytoma",
        "Recurrent Ectomesenchymoma",
        "Recurrent Ependymoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Hepatoblastoma",
        "Recurrent Kidney Wilms Tumor",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Glioma",
        "Recurrent Medulloblastoma",
        "Recurrent Melanoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdoid Tumor of the Kidney",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Recurrent WHO Grade 2 Glioma",
        "Refractory Adrenal Gland Pheochromocytoma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma",
        "Refractory Hepatoblastoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Glioma",
        "Refractory Medulloblastoma",
        "Refractory Melanoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdoid Tumor of the Kidney",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Refractory Thyroid Gland Carcinoma",
        "Refractory WHO Grade 2 Glioma"
      ],
      "interventions": [
        {
          "name": "Tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 5,
      "start_date": "2020-10-13",
      "completion_date": "2027-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 171,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04284774"
    },
    {
      "nct_id": "NCT01305200",
      "title": "Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Acute Myeloid Leukemia in Remission",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Myelodysplastic Syndromes",
        "Chronic Eosinophilic Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Neutrophilic Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Disseminated Neuroblastoma",
        "Juvenile Myelomonocytic Leukemia",
        "Mucositis",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Wilms Tumor and Other Childhood Kidney Tumors",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "supersaturated calcium phosphate rinse",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "4 Years to 21 Years"
      },
      "enrollment_count": 226,
      "start_date": "2011-03",
      "completion_date": "2015-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 31,
      "location_summary": "Arcadia, California • Duarte, California • Oakland, California + 26 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01305200"
    },
    {
      "nct_id": "NCT04483778",
      "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Solid Tumor",
        "Germ Cell Tumor",
        "Retinoblastoma",
        "Hepatoblastoma",
        "Wilms Tumor",
        "Rhabdoid Tumor",
        "Carcinoma",
        "Osteosarcoma",
        "Ewing Sarcoma",
        "Rhabdomyosarcoma",
        "Synovial Sarcoma",
        "Clear Cell Sarcoma",
        "Malignant Peripheral Nerve Sheath Tumors",
        "Desmoplastic Small Round Cell Tumor",
        "Soft Tissue Sarcoma",
        "Neuroblastoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "second generation 4-1BBζ B7H3-EGFRt-DHFR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "0 Years to 26 Years"
      },
      "enrollment_count": 68,
      "start_date": "2020-07-13",
      "completion_date": "2040-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-07-23T04:38:16.547Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04483778"
    }
  ]
}